Pieris Pharmaceuticals, Inc. (PIRS)

Trade PIRS now with
11/7/2018 7:19:01 AM Pieris Q3 Net Loss $6.2 Mln Or $0.11/Shr Vs Net Loss $7.1 Mln Or $0.16/Shr Last Year
10/25/2018 8:18:10 AM Pieris Pharmaceuticals Adds Matthew Sherman To Board
8/9/2018 7:18:20 AM Pieris Pharma Q2 Net Loss $0.2 Mln Or Breakeven Per Share Vs Loss $10.1 Mln Or $0.23/Shr Last Year
5/10/2018 7:19:35 AM Pieris Pharma Q1 Net Loss $8.7 Mln Or $0.17/shr Vs. Net Loss $8.0 Mln Or $0.19/shr Last Year
4/25/2018 8:07:16 AM Pieris Pharma Appoints Ann Barbier To Board
3/9/2018 6:05:09 AM Pieris Pharma FY Net Loss $17.6 Mln Or $0.40/Shr Vs Loss $22.8 Mln Or $0.55/Shr Last Year
2/14/2018 12:33:37 AM Pieris Pharma Prices Public Offering Of 5.5 Mln Shares At $8/Shr
2/9/2018 6:45:57 AM Seattle Genetics And Pieris Pharma Announce Multi-Program Immuno-Oncology Collaboration
12/7/2017 8:36:44 AM Pieris Reports Ethics And Regulatory Clearance To Begin Clinical Testing Of Inhaled Respiratory Program, PRS-060/AZD1402
8/10/2017 8:05:36 AM Pieris Pharma Names Allan Reine CFO
6/12/2017 8:35:41 AM Pieris Pharma Announces Expiration Of HSR Waiting Period For Collaboration With AstraZeneca
5/22/2017 4:33:28 PM Pieris Pharmaceuticals Appoints James Geraghty To Its Board Of Directors
5/3/2017 2:21:01 AM Pieris Pharma, AstraZeneca To Develop And Commercialize Anticalin-Based Inhaled Treatments For Respiratory Diseases